
Acutus Medical AFIB
Quarterly report 2024-Q3
added 11-14-2024
Acutus Medical General and Administrative Expenses 2011-2026 | AFIB
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Acutus Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 M | 20.3 M | 63.5 M | 50.4 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 63.5 M | 14.1 M | 37.1 M |
Quarterly General and Administrative Expenses Acutus Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.32 M | 2.22 M | 3.34 M | - | 2.35 M | 3.28 M | 4.47 M | - | 9.68 M | 14.1 M | 14.4 M | - | 15.8 M | 15.6 M | 16.3 M | - | 15.8 M | 9.12 M | 10.2 M | - | 7.98 M | 6.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.3 M | 2.22 M | 9.06 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Align Technology
ALGN
|
1.76 B | $ 184.69 | 2.23 % | $ 13.8 B | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
AxoGen
AXGN
|
44.6 M | $ 34.46 | 2.96 % | $ 1.59 B | ||
|
BioSig Technologies
BSGM
|
67.5 M | - | 37.08 % | $ 85.7 M | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 12.77 | 3.65 % | $ 1.73 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 292.23 | 1.41 % | $ 8.24 B | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.59 | 0.67 % | $ 36.7 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 3.37 | 1.35 % | $ 126 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 39.9 | 2.18 % | $ 5.94 K | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 63.82 | 1.01 % | $ 94.5 B | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Inogen
INGN
|
67.4 M | $ 6.34 | -1.71 % | $ 169 M | ||
|
IRIDEX Corporation
IRIX
|
7.73 M | $ 1.03 | - | $ 17.4 M | ||
|
ClearPoint Neuro
CLPT
|
16.5 M | $ 10.38 | 3.7 % | $ 294 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Second Sight Medical Products
EYES
|
1.11 M | - | -0.97 % | $ 54.4 M | ||
|
Electromed
ELMD
|
39.3 M | $ 25.21 | 1.47 % | $ 213 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
LENSAR
LNSR
|
45.2 M | $ 6.04 | 2.03 % | $ 72.2 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Globus Medical
GMED
|
1.18 B | $ 94.94 | 2.11 % | $ 12.8 B | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 1.98 | -2.46 % | $ 1.2 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 4.44 | 3.74 % | $ 940 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Myomo
MYO
|
14 M | $ 0.79 | 8.49 % | $ 33.1 M | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 17.86 | 5.37 % | $ 419 M | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 10.88 | 4.11 % | $ 390 M | ||
|
Inspire Medical Systems
INSP
|
625 M | $ 56.83 | 3.48 % | $ 1.67 B | ||
|
CONMED Corporation
CNMD
|
132 M | $ 39.73 | 3.3 % | $ 1.23 B | ||
|
LivaNova PLC
LIVN
|
549 M | $ 64.99 | 0.63 % | $ 3.55 B | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 88.63 | 1.03 % | $ 3.08 B | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.76 | 0.27 % | $ 123 M | ||
|
Invacare Corporation
IVC
|
227 M | - | - | $ 24.7 M | ||
|
Edwards Lifesciences Corporation
EW
|
2.09 B | $ 78.2 | 0.1 % | $ 45.7 B |